Pharmacogenomics Services Market - A Global and Regional Analysis
Title:
Pharmacogenomics Services Market - A Global and Regional Analysis
Description:
The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. – PowerPoint PPT presentation
Number of Views:0
Title: Pharmacogenomics Services Market - A Global and Regional Analysis
1
Pharmacogenomics Services Market - A Global and
Regional Analysis
res tion
https//pixabay.com/photos/tire-rim-car-mechanic-1
14259/
Table of Content
Attribu
t e k r a M s e c i v r e S s c i m o n
e g o c a m
Focus on Service, Technology, Application, End
User, and Country-Wise Analysis Analysis and
Forecast 2021-2031 January 2022
r a h 1 P All rights reserved at BIS Research
Inc.
2
BIS Research is a leading market intelligence and
technology research company. BIS Research
publishes in- depth market intelligence reports
focusing on the market estimations, technology
analysis, emerging high- growth applications,
deeply segmented granular country-level market
data and other important market parameters
useful in the strategic decision making for
senior management. BIS Research provides
multi-client reports, company profiles,
databases, and custom research services.
Pharmacogenomics Services Market
Copyright 2022 BIS Research Inc. All Rights
Reserved. This document contains highly
confidential information and is the sole property
of BIS Research. Disclosing, copying,
circulating, quoting, or otherwise reproducing
any or all contents of this document is strictly
prohibited. Access to this information is
provided exclusively for the benefit of the
people or organization concerned. It may not be
accessed by or offered whether for sale or
otherwise to any third party.
2
3
- Table of Content
- Executive Summary.................................
.........................................20 - 1. Market ........................................
...............................................27 - 1.1 Product Definition............................
..................................................
..............28 - 1.1.1 Inclusion and Exclusion
..................................................
...........................28 - 1.2 Market Scope .................................
..................................................
................28 - 1.2.1 Scope of the Study .........................
..................................................
...........28 1.2.2 Key Questions Answered in
the Report .......................................
.............29 - 1.3 Research Methodology .........................
..................................................
........30 - 1.3.1 Global Pharmacogenomics Services Market Re
search Methodology ..............................
..................................................
................30 - 1.3.2 Data Sources .............................
..................................................
................31 - 1.3.2.1 Primary Data Sources.....................
..................................................
................. 31 - 1.3.2.2 Secondary Data Sources....................
..................................................
............. 31 - 1.3.3 Market Estimation Model
..................................................
..........................32 - 1.3.4 Criteria for Company Profiling
..................................................
.................34 - 1.4 Market Overview ..............................
..................................................
..............34 - 1.4.1 Market Definition ..........................
..................................................
.............34 - Emerging Applications of Pharmacogenomics
Services ........................35 - Significant Services in the Pharmacogenomics
Ecosystem ...................36 - Market Footprint and Growth Potential, Million,
2020-2031 ...................36
Pharmacogenomics Services Market
4
- 2.3.1 China ....................................
..................................................
......................46 - 2.3.2 Japan ....................................
..................................................
......................48 - 3. Market Dynamics ...............................
.......................................51 - 3.1 Overview..................................
..................................................
.......................52 - 3.2 Iceberg Analysis - Global Pharmacogenomics
Services Market.................52 3.3 Impact
Analysis .........................................
..................................................
....53 3.4 Market Drivers...................
..................................................
.............................54 - Increasing Prevalence of Infectious Diseases and
Various Types of Cancer Globally
..................................................
.........................................54 - Increase in Adoption of Personalized Medicine
Shifting the Paradigm from Reaction to
Prevention on a Global Level......................
.56 - 3.4.3 Increasing Rate of Adverse Drug Reaction
...............................................56 - 3.4.4 Surge in Usage of Pharmacogenomics for Drug
Discovery and Development .......................
..................................................
.......................57 - 3.5 Market Restraints.............................
..................................................
..............58 - 3.5.1 Lack of Use of Available Data for Drug
Development Initiatives.............58 3.5.2
Lack of High Complexity Testing
Centers...........................................
......59 - Difficulties in Detecting Gene Variation
Affecting Drug Response.........59 - Regulatory Challenges for Direct-to-Consumer
(DTC) Pharmacogenomics Companies
..................................................
..............60 - 3.6 Market Opportunities..........................
..................................................
...........61 - Massive Scope for Adoption of Pharmacogenomics in
Emerging Nations ................................
..................................................
.......................61 - Technological Advancements in Molecular Techniques
for Pharmacogenomic Diagnostic
Tests.............................................
............61 - Rise of Direct-to-Consumer (DTC) Testing
Services................................63
4. Competitive Landscape..........................
...................................64
4.1 Overview.....................................
..................................................
....................65 - 4
Pharmacogenomics Services Market
5
4.2 Synergistic Activities .......................
..................................................
.............65 4.3 Product Approvals.............
..................................................
............................66 4.4 Product
Launches .........................................
..................................................
67 4.5 Business Expansion, Funding, and
Reimbursement Activities ..................68 4.6
Mergers and Acquisitions .........................
..................................................
....69 4.7 Market Share Analysis, 2019 and 2020
..................................................
........69 4.8 Growth Share Analysis
..................................................
.................................71 4.8.1
Growth Share Analysis (by Company)
..................................................
....71 4.8.2 Growth Share Analysis (by
Technology).......................................
............73 4.8.3 Growth Share Analysis (by
Application) .....................................
..............74 5. Service, Million,
2020-2031.........................................
.............76 5.1 Overview......................
..................................................
...................................77 5.2 Genotypi
ng................................................
..................................................
.....78 5.3 SNP Identification ...................
..................................................
.......................80 5.4 Pharmacogenetic
Testing ..........................................
.....................................81 5.5 Other
Services .........................................
..................................................
......82 6. Technology, Million, 2020 2031
.............................................84 6.
1 Overview........................................
..................................................
.................85 6.2 Polymerase Chain Reaction
(PCR).............................................
....................86 6.3 Microarray
..................................................
..................................................
....88 6.4 Sequencing ............................
..................................................
........................90 6.5 Other Technologies
..................................................
.......................................92 7. Appli
cation, Million, 20202031 ......................
..........................94 7.1 Overview.........
..................................................
................................................95
7.2 Oncology ....................................
..................................................
....................96 7.3 Infectious Diseases
..................................................
.......................................98 7.4 Neur
ology/Psychiatry .................................
..................................................
...99 5
Pharmacogenomics Services Market
6
- 7.5 Cardiovascular................................
..................................................
.............100 - 7.6 Other Applications............................
..................................................
...........101 - 8. End User, Million, 2020-2031
.................................................
103 - 8.1 Overview......................................
..................................................
.................104 - 8.2 Research Organizations........................
..................................................
......105 - 8.2.1 Global Pharmacogenomics Services Market (Re
search Organizations, by Service)
..................................................
.....................106 - 8.3 Pharmaceutical Companies .....................
..................................................
...107 - 8.3.1 Global Pharmacogenomics Services Market (Ph
armaceutical Companies, by Service)
..................................................
..........................108 - 8.4 Diagnostic Centers ...........................
..................................................
...........109 - 8.4.1 Global Pharmacogenomics Services Market
(Diagnostic Centers, - by Service) ......................................
..................................................
.........110 - 8.5 Other End Users ..............................
..................................................
............111 - 8.5.1 Global Pharmacogenomics Services Market
(Other End Users, by Service) ...................
..................................................
.................................112 - 9. Region, Million, 2020-2031 ...................
.................................. 113 - 9.1 Overview......................................
..................................................
.................114 - 9.2 North America ................................
..................................................
..............116 - 9.2.1 U.S. .....................................
..................................................
......................119 - 9.2.2 Canada ...................................
..................................................
..................120 - North America Pharmacogenomics Services Market (by
Application)....................................
..................................................
..........121
Pharmacogenomics Services Market
7
- 9.3.4 Italy ....................................
..................................................
.......................129 - 9.3.5 Spain......................................
..................................................
...................130 - 9.3.6 Denmark ..................................
..................................................
.................132 - 9.3.7 Netherlands................................
..................................................
..............133 - 9.3.8 Rest-of-Europe.............................
..................................................
............134 - Europe Pharmacogenomics Services Market (by
Application) .............134 - Europe Pharmacogenomics Services Market (by
Service)....................135 - 9.4 Asia-Pacific .................................
..................................................
.................136 - 9.4.1 Japan ....................................
..................................................
....................138 - 9.4.2 China ....................................
..................................................
....................139 - 9.4.3 Australia .................................
..................................................
..................141 - 9.4.4 India .....................................
..................................................
.....................142 - 9.4.5 Singapore ................................
..................................................
.................143 - 9.4.6 Rest-of-Asia-Pacific (RoAPAC)
..................................................
..............144 - Asia-Pacific Pharmacogenomics Services Market (by
Application) .....145 - Asia-Pacific Pharmacogenomics Services Market (by
Service)............146 9.5 Latin America
..................................................
...............................................148
- 9.5.1 Brazil.....................................
..................................................
....................150 - 9.5.2 Mexico ...................................
..................................................
...................151 - 9.5.3 Rest-of-Latin America (RoLA)
..................................................
................152
Pharmacogenomics Services Market
8
10. Company Profiles..............................
......................................
158 10.1 Overview.................................
..................................................
......................159 10.2 Abbott
Laboratories .....................................
.................................................1
60 10.2.1 Company Overview .......................
..................................................
..........160 10.2.2 Role of Abbott Laboratories
in the Global Pharmacogenomics Services Market
..................................................
.......................................160 10.2.3
Financials .......................................
..................................................
..........161 10.2.4 Key Insights about Financial
Health of the Company ............................
163 10.2.5 SWOT Analysis .........................
..................................................
...............164 10.3 Admera Health, LLC
..................................................
....................................165 10.3.1
Company Overview .................................
..................................................
165 10.3.2 Role of Admera Health, LLC in the
Global Pharmacogenomics Services Market
..................................................
.......................................165 10.3.3
SWOT Analysis ....................................
..................................................
....166 10.4 Mesa Laboratories, Inc.
..................................................
...............................167 10.4.1 Company
Overview .........................................
..........................................167 10.4
.2 Role of Mesa Laboratories, Inc. in the Global
Pharmacogenomics Services Market
..................................................
.......................................167 10.4.3
Financials .......................................
..................................................
..........168 10.4.4 Key Insights about Financial
Health of the Company ............................
169 10.4.5 SWOT Analysis .........................
..................................................
...............170 10.5 Dynamic DNA Laboratories
..................................................
........................171 10.5.1 Company
Overview .........................................
..........................................171 10.5
.2 Role of Dynamic DNA Laboratories in the Global
Pharmacogenomics Services Market
..................................................
....171 10.5.3 SWOT Analysis .....................
..................................................
...................172 10.6 F. Hoffmann-La Roche
Ltd. .............................................
..............................173 10.6.1 Company
Overview .........................................
..........................................173 8
Pharmacogenomics Services Market
9
10.6.2 Role of F. Hoffmann La-Roche Ltd. in the Gl
obal Pharmacogenomics Services Market
..................................................
....173 10.6.3 Financials ........................
..................................................
.........................175 10.6.4 Key Insights
about Financial Health of the Company
............................177 10.6.5 SWOT
Analysis .........................................
.................................................1
78 10.7 geneOmbio Technologies Pvt Ltd.
..................................................
.............179 10.7.1 Company Overview
..................................................
.................................179 10.7.2
Role of geneOmbio Technologies Pvt Ltd. in the Glo
bal Pharmacogenomics Services Market
..................................................
....179 10.7.3 SWOT Analysis .....................
..................................................
...................180 10.8 Exact Sciences
Corporation ......................................
...................................181 10.8.1
Company Overview .................................
..................................................
181 10.8.2 Role of Exact Sciences Corporation in t
he Global Pharmacogenomics Services Market
..................................................
....181 10.8.3 Financials ........................
..................................................
.........................183 10.8.4 Key Insights
about Financial Health of the Company
............................184 10.8.5 SWOT
Analysis .........................................
.................................................1
85 10.9 Illumina, Inc. ...........................
..................................................
......................186 10.9.1 Company Overview
..................................................
.................................186 10.9.2 Role
of Illumina, Inc. in the Global Pharmacogenomics
Services Market..................................
..................................................
.....................186 10.9.3 Financials
..................................................
.................................................1
88 10.9.4 Key Insights about Financial Health of
the Company ............................190
10.9.5 SWOT Analysis .............................
..................................................
...........191 10.10 Laboratory Corporation of
America Holdings..................................
...........192 10.10.1 Company Overview...........
..................................................
................192 10.10.2 Role of Laboratory
Corporation of America Holdings in the Global
Pharmacogenomics Services Market
..........................................192 9
Pharmacogenomics Services Market
10
10.10.3 Financials ...............................
..................................................
...........193 10.10.4 SWOT Analysis..............
..................................................
....................195 10.11 Myriad Genetics,
Inc. .............................................
........................................196 10.11.
1 Company Overview................................
.............................................196 1
0.11.2 Role of Myriad Genetics, Inc. in the
Global Pharmacogenomics Services Market
..................................................
.......................................196 10.11.3
Financials ......................................
..................................................
....197 10.11.4 Key Insights about Financial
Health of the Company......................199 10.
11.5 SWOT Analysis................................
..................................................
..200 10.12 OmeCare...............................
..................................................
........................201 10.12.1 Company
Overview..........................................
...................................201 10.12.2 Rol
e of OmeCare in the Global Pharmacogenomics
Services Market..................................
..................................................
.....................201 10.12.3 SWOT
Analysis..........................................
..........................................202 10.1
3 QIAGEN N.V......................................
..................................................
............203 10.13.1 Company
Overview..........................................
...................................203 10.13.2 Rol
e of QIAGEN N.V. in the Global Pharmacogenomics
Services Market..................................
..................................................
.....................203 10.13.3 Financials
..................................................
..........................................205 10.1
3.4 Key Insights about Financial Health of the
Company......................206 10.13.5 SWOT
Analysis..........................................
..........................................207 10.1
4 Quest Diagnostics Incorporated
..................................................
................208 10.14.1 Company
Overview..........................................
...................................208 10.14.2 Rol
e of Quest Diagnostics Incorporated in the Global
Pharmacogenomics Services Market
..................................................
....208 10.14.3 Financials .......................
..................................................
...................209 10.14.4 SWOT
Analysis..........................................
..........................................211 10.1
5 Thermo Fisher Scientific Inc....................
..................................................
...212 10
Pharmacogenomics Services Market
11
10.15.1 Company Overview..........................
..................................................
.212 10.15.2 Role of Thermo Fisher Scientific Inc.
in the Global Pharmacogenomics Services Market
..................................................
....212 10.15.3 Financials .......................
..................................................
...................213 10.15.4 Key Insights about
Financial Health of the Company...................
...215 10.15.5 SWOT Analysis......................
..................................................
............216 10.16 Precipio ...................
..................................................
.....................................217 10.16.1 C
ompany Overview...................................
..........................................217 10.1
6.2 Role of Precipio in the Global
Pharmacogenomics Services Market.................
..................................................
......................................217 10.16.3
Financials .......................................
..................................................
...218 10.16.4 SWOT Analysis......................
..................................................
............219 10.17 23andMe, Inc.
..................................................
...............................................220
10.17.1 Company Overview.........................
..................................................
..220 10.17.2 Role of 23andMe, Inc. in the Global
Pharmacogenomics Services Market
..................................................
.......................................220 10.17.3
SWOT Analysis....................................
................................................22
1 10.18 OneOme, LLC..............................
..................................................
.................222 10.18.1 Company
Overview..........................................
...................................222 10.18.2 Rol
e of OneOme, LLC in the Global Pharmacogenomics
Services Market ..................................
..................................................
.....222 10.18.3 SWOT Analysis....................
..................................................
..............223 10.19 DiaCarta,
Inc...............................................
..................................................
..224 10.19.1 Company Overview....................
..................................................
.......224 10.19.2 Role of DiaCarta, Inc. in the
Global Pharmacogenomics Services Market
..................................................
.......................................224 10.19.3
SWOT Analysis....................................
................................................22
6 10.20 OPKO Health .............................
..................................................
...................227
Pharmacogenomics Services Market
12
10.20.1 Company Overview..........................
..................................................
.227 10.20.2 Role of OPKO Health in the Global
Pharmacogenomics Services Market
..................................................
.......................................227 10.20.3
Financials ......................................
..................................................
....228 10.20.2 Key Insights About Financial
Health of the Company .....................230
10.20.3 SWOT Analysis.............................
..................................................
.....231
Pharmacogenomics Services Market
13
List of Figures
Figure 1 Figure 2
Estimates for Global Healthcare Market, 2018 and
2020 Impact Analysis of Market Drivers and
Challenges on the Global Pharmacogenomics
Services Market Global Pharmacogenomics Services
Market (by Service), Million, 2020 and
2031 Global Pharmacogenomics Services Market (by
Application), Million, 2020 and 2031 Global
Pharmacogenomics Services Market (by Technology),
Million, 2020 and 2031 Global Pharmacogenomics
Services Market (by End User), Million, 2020 and
2031 Global Pharmacogenomics Services Market
Snapshot Global Pharmacogenomics Services Market
Segmentation Global Pharmacogenomics Services
Market Methodology
Figure 3 Figure 4 Figure 5 Figure 6 Figure
7 Figure 8 Figure 9
Figure 10 Primary Research Methodology Figure
11 Bottom-Up Approach (Segment-Wise Analysis)
Figure 12 Top-Down Approach (Segment-Wise
Analysis) Figure 13 Global Pharmacogenomics
Services Market, Million, 2020-2031 Figure 14
Global Pharmacogenomics Services Market COVID-19
Impact Analysis Figure 15 Components Considered
for Clinical Evidence as per the IVDR Figure 16
Process of Medical Device Designation by the MHLW
and PMDA Figure 17 Number of Deaths by Top 18
Infectious Diseases, 2015 Figure 18 Number of
Deaths by Different Forms of Cancer, Million,
2020 Figure 19 Benefits of Multiplexing
Reactions Figure 20 Share of Key Developments
and Strategies, January 2018-December 2021 Figure
21 Share of Synergistic Activities (by Company),
January 2018-December 2021 Figure 22 Share of
Product Approvals (by Company), January
2018-December 2021 Figure 23 Number of Product
Launches (by Company), January 2018-December
2021 Figure 24 Share of Business Expansion,
Funding, and Reimbursement Activities (by
Company), January 2018-December 2021 Figure 25
Share of Mergers and Acquisitions (by Company),
January 2018-December 2021 Figure 26 Market
Share Analysis for the Global Pharmacogenomics
Services Market, Million, 2019 and 2020 Figure
27 Growth Share Analysis for the Global
Pharmacogenomics Services Market (by Company),
2020 Figure 28 Growth Share Analysis for the
Global Pharmacogenomics Services Market (by
Technology), 2020-2031 Figure 29 Growth Share
Analysis for the Global Pharmacogenomics Services
Market (by Application), 2020-2031 Figure 30
Global Pharmacogenomics Services Market (by
Service) Figure 31 Global Pharmacogenomics
Services Market (by Service), 2020 and
2031 Figure 32 Global Pharmacogenomics Services
Market (by Genotyping), Million, 2020-2031
Figure 33 Global Pharmacogenomics Services
Market (by SNP Identification), Million,
2020-2031 13
Pharmacogenomics Services Market
14
Figure 34 Global Pharmacogenomics Services
Market (by Pharmacogenetic Testing), Million,
2020- 2031 Figure 35 Global Pharmacogenomics
Services Market (by Other Services), Million,
2020-2031 Figure 36 Global Pharmacogenomics
Services Market (by Technology) Figure 37 Global
Pharmacogenomics Services Market (by Technology),
Million, 2020 and 2031 Figure 38 Global
Pharmacogenomics Services Market (by PCR),
Million, 2020-2031 Figure 39 Global
Pharmacogenomics Services Market (by Microarray),
Million, 2020-2031 Figure 40 Evolution of
Sequencing for Molecular Diagnostics Figure 41
Global Pharmacogenomics Services Market (by
Sequencing), Million, 2020-2031 Figure 42
Global Pharmacogenomics Services Market (by Other
Technologies), Million, 2020-2031 Figure 43
Global Pharmacogenomics Services Market (by
Application) Figure 44 Global Pharmacogenomics
Services Market (by Application), 2020 and
2031 Figure 45 Global Pharmacogenomics Services
Market (by Oncology), Million, 2020-2031 Figure
46 Global Pharmacogenomics Services Market (by
Infectious Diseases), Million, 2020-2031 Figure
47 Global Pharmacogenomics Services Market (by
Neurology/Psychiatry), Million, 2020-2031
Figure 48 Global Pharmacogenomics Services
Market (by Cardiovascular), Million, 2020-2031
Figure 49 Global Pharmacogenomics Services
Market (by Other Applications), Million,
2020-2031 Figure 50 Global Pharmacogenomics
Services Market (by End User) Figure 51 Global
Pharmacogenomics Services Market (by End User),
Million, 20202031 Figure 52 Global
Pharmacogenomics Services Market (by Research
Organizations), Million, 2020- 2031 Figure 53
Global Pharmacogenomics Services Market (Research
Organizations by Service), Share, 2020 and
2031 Figure 54 Global Pharmacogenomics Services
Market (by Pharmaceutical Companies), Million,
2020-2031 Figure 55 Global Pharmacogenomics
Services Market (Pharmaceutical Companies, by
Service), Share, 2020 and 2031 Figure 56 Global
Pharmacogenomics Services Market (by Diagnostic
Centers), Million, 2020-2031 Figure 57 Global
Pharmacogenomics Services Market (Diagnostic
Centers, by Service), Share, 2020 and 2031 Figure
58 Global Pharmacogenomics Services Market (by
Other End Users), Million, 2020-2031 Figure 59
Global Pharmacogenomics Services Market (Other
End Users, by Service), Share, 2020 and
2031 Figure 60 Global Pharmacogenomics Services
Market Snapshot (by Region) Figure 61 Global
Pharmacogenomics Services Market (by Region),
Million, 2020-2031 Figure 62 Global
Pharmacogenomics Services Market (by Region),
2020 and 2031 Figure 63 North America
Pharmacogenomics Services Market, Million,
2020-2031 Figure 64 North America
Pharmacogenomics Services Market (by Country),
Million, 2020-2031 Figure 65 U.S.
Pharmacogenomics Services Market, Million,
2020-2031 Figure 66 Canada Pharmacogenomics
Services Market, Million, 2020-2031 Figure 67
North America Pharmacogenomics Services Market
(by Application), Share, 2020 and 2031 Figure
68 North America Pharmacogenomics Services
Market (by Service), Share, 2020 and 2031 14
Pharmacogenomics Services Market
15
Figure 69 Europe Pharmacogenomics Services
Market, Million, 2020-2031 Figure 70 Europe
Pharmacogenomics Services Market (by Country),
Million, 20202031 Figure 71 Germany
Pharmacogenomics Services Market, Million,
2020-2031 Figure 72 U.K. Pharmacogenomics
Services Market, Million, 2020-2031 Figure 73
France Pharmacogenomics Services Market,
Million, 2020-2031 Figure 74 Italy
Pharmacogenomics Services Market, Million,
2020-2031 Figure 75 Spain Pharmacogenomics
Services Market, Million, 2020-2031 Figure 76
Denmark Pharmacogenomics Services Market,
Million, 2020-2031 Figure 77 Netherlands
Pharmacogenomics Services Market, Million,
2020-2031 Figure 78 Rest-of-Europe
Pharmacogenomics Services Market, Million,
2020-2031 Figure 79 Europe Pharmacogenomics
Services Market (by Application), Share, 2020 and
2031 Figure 80 Europe Pharmacogenomics Services
Market (by Service), Share, 2020 and 2031 Figure
81 Asia-Pacific Pharmacogenomics Services
Market, Million, 2020-2031 Figure 82 APAC
Pharmacogenomics Services Market (by Country),
Million, 2020-2031 Figure 83 Japan
Pharmacogenomics Services Market, Million,
2020-2031 Figure 84 China Pharmacogenomics
Services Market, Million, 2020-2031 Figure 85
Australia Pharmacogenomics Services Market,
Million, 2020-2031 Figure 86 India
Pharmacogenomics Services Market, Million,
2020-2031 Figure 87 Singapore Pharmacogenomics
Services Market, Million, 2020-2031 Figure 88
Rest-of-Asia-Pacific Pharmacogenomics Services
Market, Million, 2020-2031 Figure 89
Asia-Pacific Pharmacogenomics Services Market (by
Application), Share, 2020 and 2031 Figure 90
Asia-Pacific Pharmacogenomics Services Market (by
Service), Share, 2020 and 2031 Figure 91 Latin
America Pharmacogenomics Services Market,
Million, 2020-2031 Figure 92 Latin America
Pharmacogenomics Services Market (by Country),
Million, 2020-2031 Figure 93 Brazil
Pharmacogenomics Services Market, Million,
2020-2031 Figure 94 Mexico Pharmacogenomics
Services Market, Million, 2020-2031 Figure 95
Rest-of-Latin America Pharmacogenomics Services
Market, Million, 2020-2031 Figure 96 Latin
America Pharmacogenomics Services Market (by
Application), Share, 2020 and 2031 Figure 97
Latin America Pharmacogenomics Services Market
(by Service), Share, 2020 and 2031 Figure 98
Rest-of-the-World Pharmacogenomics Services
Market, Million, 2020-2031 Figure 99
Rest-of-the-World Pharmacogenomics Services
Market (by Application), Share, 2020 and 2031
Pharmacogenomics Services Market
Rest-of-the-World Pharmacogenomics Services
Market (by Service), Share, 2020 and 2031 Total
Number of Companies Profiled Abbott
Laboratories Portfolio Abbott Laboratories
Overall Financials, Million, 2018-2020 Abbott
Laboratories Revenue (by Segment), Million,
2018-2020 Abbott Laboratories Revenue (by
Region), Million, 2018-2020 Abbott
Laboratories RD Expenditure, Million,
2018-2020 Abbott Laboratories SWOT Analysis
Figure 100
Figure 101 Figure 102 Figure 103 Figure
104 Figure 105 Figure 106 Figure 107
15
16
Figure 108 Figure 109 Figure 110 Figure
111 Figure 112 Figure 113 Figure 114 Figure
115 Figure 116 Figure 117 Figure 118 Figure
119 Figure 120 Figure 121 Figure 122 Figure
123 Figure 124 Figure 125 Figure 126 Figure
127 Figure 128 Figure 129 Figure 130 Figure
131 Figure 132 Figure 133 Figure 134 Figure
135 Figure 136 Figure 137 Figure 138 Figure
139 Figure 140 Figure 141 Figure 142 Figure
143 Figure 144 Figure 145 Figure 146 Figure
147 Figure 148
Admera Health, LLC Portfolio Admera Health,
LLC SWOT Analysis Mesa Laboratories, Inc.
Portfolio Mesa Laboratories, Inc. Overall
Financials, Million, 2018-2020 Mesa
Laboratories, Inc. Revenue (by Segment),
Million, 2018-2020 Mesa Laboratories, Inc. RD
Expenditure, Million, 2018-2020 Mesa
Laboratories, Inc. SWOT Analysis Dynamic DNA
Laboratories Portfolio Dynamic DNA
Laboratories SWOT Analysis F. Hoffmann-La Roche
Ltd. Portfolio F. Hoffmann-La Roche Ltd.
Overall Financials, Million, 2018-2020 F.
Hoffmann-La Roche Ltd. Revenue (by Segment),
Million, 2018-2020 F. Hoffmann-La Roche Ltd.
Revenue (by Region), Million, 2018-2020 F.
Hoffmann-La Roche Ltd. RD Expenditure,
Million, 2018-2020 F. Hoffmann-La Roche Ltd.
SWOT Analysis geneOmbio Technologies Pvt Ltd.
Portfolio geneOmbio Technologies Pvt Ltd. SWOT
Analysis Exact Sciences Corporation
Portfolio Exact Sciences Corporation Overall
Financials, Million, 2018-2020 Exact Sciences
Corporation Revenue (by Segment), Million,
2018-2020 Exact Sciences Corporation Revenue
(by Region), Million, 2018-2020 Exact Sciences
Corporation RD Expenditure, Million, 2018-2020
Exact Sciences Corporation SWOT
Analysis Illumina, Inc. Portfolio Illumina,
Inc. Overall Financials, Million, 2018-2020
Illumina, Inc. Revenue (by Segment), Million,
2018-2020 Illumina, Inc. Revenue (by Region),
Million, 2018-2020 Illumina, Inc. RD
Expenditure, Million, 2018-2020 Illumina, Inc.
SWOT Analysis Laboratory Corporation of America
Holdings Portfolio Laboratory Corporation of
America Holdings Overall Financials, Million,
2018-2020 Laboratory Corporation of America
Holdings Revenue (by Segment), Million,
2018-2020 Laboratory Corporation of America
Holdings Revenue (by Region), Million,
2018-2020 Laboratory Corporation of America
Holdings SWOT Analysis Myriad Genetics, Inc.
Portfolio Myriad Genetics, Inc. Overall
Financials, Million, 2018-2020 Myriad Genetics,
Inc. Revenue (by Segment), Million, 2018-2020
Myriad Genetics, Inc. Revenue (by Region),
Million, 2018-2020 Myriad Genetics, Inc. RD
Expenditure, Million, 2018-2020 Myriad
Genetics, Inc. SWOT Analysis OmeCare Portfolio
Pharmacogenomics Services Market
17
Figure 149 Figure 150 Figure 151 Figure
152 Figure 153 Figure 154 Figure 155 Figure
156 Figure 157 Figure 158 Figure 159 Figure
160 Figure 161 Figure 162 Figure 163 Figure
164 Figure 165 Figure 166 Figure 167 Figure
168 Figure 169 Figure 170 Figure 171 Figure
172 Figure 173 Figure 174 Figure 175 Figure
176 Figure 177 Figure 178 Figure 179 Figure
180
OmeCare SWOT Analysis QIAGEN N.V.
Portfolio QIAGEN N.V. Overall Financials,
Million, 2018-2020 QIAGEN N.V. Revenue (by
Segment), Million, 2018-2020 QIAGEN N.V.
Revenue (by Region), Million, 2018-2020 QIAGEN
N.V. RD Expenditure, Million, 2018-2020
QIAGEN N.V. SWOT Analysis Quest Diagnostics
Incorporated Portfolio Quest Diagnostics
Incorporated Overall Financials, Million,
2018-2020 Quest Diagnostics Incorporated Revenue
(by Segment), Million, 2018-2020 Quest
Diagnostics Incorporated SWOT Analysis Thermo
Fisher Scientific Inc. Portfolio Thermo Fisher
Scientific Inc. Overall Financials, Million,
2018-2020 Thermo Fisher Scientific Inc. Revenue
(by Segment), Million, 2018-2020 Thermo Fisher
Scientific Inc. Revenue (by Region), Million,
2018-2020 Thermo Fisher Scientific Inc. RD
Expenditure, Million, 2018-2020 Thermo Fisher
Scientific Inc. SWOT Analysis Precipio
Portfolio Precipio Overall Financials, Million,
2018-2020 Precipio SWOT Analysis 23andMe, Inc.
Portfolio 23andMe, Inc. SWOT Analysis OneOme,
LLC Portfolio OneOme, LLC SWOT Analysis
DiaCarta, Inc. Portfolio DiaCarta, Inc. SWOT
Analysis OPKO Health Portfolio OPKO Health
Overall Financials, Million, 2018-2020 OPKO
Health Revenue (by Segment), Million, 20182020
OPKO Health Revenue (by Region), Million,
2018-2020 OPKO Health RD Expenditure,
Million, 2018-2020 OPKO Health SWOT Analysis
Pharmacogenomics Services Market
18
List of Tables
Table 1 Table 2 Table 3 Table 4 Table
5 Table 6 Table 7 Table 8 Table 9 Table 10
Classification Rules of IVDs under the
IVDR Registration Criteria for IVD Medical
Devices as per the NMPA Likert Scale Impact
Analysis of Market Drivers Impact Analysis of
Market Restraints Examples of Adverse Drug
Reactions North America Market Dynamics
Europe Market Dynamics APAC Market
Dynamics Latin America Market Dynamics
Pharmacogenomics Services Market
19
BIS Research Offerings We are on a mission to
harness the potential of disruptive technologies
to make businesses thrive in todays digital
age. We have the vision to be a leading and
preferred knowledge partner for corporates and
institutions worldwide and assist them with
market intelligence in the area of emerging
technologies, advisories, and other innovative
solutions.
Know More
Know More
Know More
Pharmacogenomics Services Market
Know More
20
Disclaimer BIS Research Inc. provides valuable
market intelligence to an exclusive group of
customers in response to orders. The report is
licensed for the customer's internal use only and
is subject to restrictions set henceforth. This
document and its contents are confidential and
may not be further distributed, published or
reproduced, in whole or in part, by any medium
or in any form for any purpose, without the
express written consent of BIS Research Inc.
Customer will not disclose the contents of the
report, whether directly in any media or
indirectly through incorporation in a database,
marketing list, report or otherwise, or use or
permit the use of Information to generate any
statistical or other information that is or will
be provided to third parties or voluntarily
produce Information in legal proceedings. Marke
t reports are based on expectations, estimates
and projections as of the date such information
is available. Any recommendation contained in
this report may not be suitable for all investors
or businesses. The market conclusions drawn are
necessarily based upon a number of estimates and
assumptions that, while considered reasonable by
BIS Research Inc. as of the date of such
statements, are inherently subject to market
fluctuations and business, economic and
competitive uncertainties and contingencies For
more details regarding permission, please contact
us Email sales_at_bisresearch.com Tel 1 510 404
8135
Pharmacogenomics Services Market
21
BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite
313 Fremont, CA 94538 -1686 E-mail
hello_at_bisresearch.com Call Us 1-510-404-8135
t e k r a M s e c i v r e S s c i m o
n e g o c a m r a h 21 P All rights
reserved at BIS Research Inc.
Global Delivery Center Tower B First Floor,
Tapasya Corporate Heights, Greater Noida
Expressway, Sector 126, Noida, U.P., 201303,
India Tel 91 120 4261540 / 4261544
www.bisresearch.com
Recommended
CrystalGraphics Presentations
